SECALCIFEROL

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C27H44O3
Molecular Weight	416.6365
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	2
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@H](CC[C@@H](O)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C3\C[C@@H](O)CCC3=C

InChI

InChIKey=FCKJYANJHNLEEP-XRWYNYHCSA-N

InChI=1S/C27H44O3/c1-18-8-12-22(28)17-21(18)11-10-20-7-6-16-27(5)23(13-14-24(20)27)19(2)9-15-25(29)26(3,4)30/h10-11,19,22-25,28-30H,1,6-9,12-17H2,2-5H3/b20-10+,21-11-/t19-,22+,23-,24+,25-,27-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C27H44O3
Molecular Weight	416.6365
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	6 / 6
E/Z Centers	2
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9770350
Curator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/12431790 https://www.ncbi.nlm.nih.gov/pubmed/27257472

Secalciferol (24,25-DIHYDROXYVITAMIN D 3/24R,25(OH)(2)D(3)) is suggested to be an essential hormone for the process of bone fracture healing, it has a physiological role in human bone and mineral metabolism, leading to an enhancement of osteocalcin synthesis. Secalciferol is possibly to bind a nuclear protein vitamin D receptor (VDR) to the ligand binding domain, which is stereo-specific for Secalciferol. The downstream effect will be triggered after the binding, including the inhibition of calcium channel to regulate the calcium homeostasis, and the following reduction of p53 and Pi-induced cytochrome C translocation

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Vitamin D receptor 25 Target ID: CHEMBL1977 Sources: http://www.ncbi.nlm.nih.gov/pubmed/12431790	Binding Agent 1076

Conditions

Condition	Modality	Targets	Highest Phase	Product
Bone disease 70 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9770350	Primary		Basic research	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Vitamin D3 compounds regulate human immunodeficiency virus type 1 replication in U937 monoblastoid cells and in monocyte-derived macrophages.	1993-02	8383166

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Unknown

In Vitro Use Guide

Treatment with 24R,25(OH)(2)D(3) (SECALCIFEROL) reduced Chondrogenic ATDC5 cell number and increased alkaline phosphatase specific activity in a dose-dependent manner. Moreover, 24R,25(OH)(2)D(3) reversed the Pi-induced decrease in incorporation of [(3)H]-thymidine and [(35)S]-sulfate incorporation, as well as the Pi-induced increase in apoptosis. These results suggest that Pi acts as an early chondrogenic differentiation factor, inducing response to 24R,25(OH)(2)D(3); treatment of committed chondrocytes with Pi induces apoptosis, but 24R,25(OH)(2)D(3) mitigates these effects, indicating a possible inhibitory feedback loop.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 19:27:26 GMT 2025` Edited by `admin` on `Mon Mar 31 19:27:26 GMT 2025`
Record UNII	460029IUDA
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

OSTEO D

Preferred Name

English

SECALCIFEROL

Official Name

English

(5Z,7E,24R)-9,10-SECOCHOLESTA-5,7,10(19)-TRIENE-3B,24,25-TRIOL

Common Name

English

2,3-HEPTANEDIOL, 2-METHYL-6-((1R,3AS,4E,7AR)-OCTAHYDRO-4-((2Z)-2-((5S)-5-HYDROXY-2-METHYLENECYCLOHEXYLIDENE)ETHYLIDENE)-7A-METHYL-1H-INDEN-1-YL)-, (3R,6R)-

Systematic Name

English

secalciferol [INN]

Common Name

English

24(R),25-(OH)2D3

Common Name

English

SECALCIFEROL [USAN]

Common Name

English

SECALCIFEROL [JAN]

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

75193